Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

Bausch + Lomb Presents Products, Surgical Platforms and Newly Expanded Retina Offerings During the Annual Meeting of the American Academy of Ophthalmology in Las Vegas

Attendees Can Participate in Live Demonstrations of Surgical Platforms

Leading Experts to Host Panel Discussions and Talks in Bausch + Lomb Booth


BRIDGEWATER, NJ — Bausch + Lomb, a leading global eye health company, will showcase its product innovations in pharmaceuticals, intraocular lenses (IOLs), surgical devices and equipment during the Annual Meeting of the American Academy of Ophthalmology (AAO) at the Sands Expo/Venetian in Las Vegas, Nevada (Nov. 14-17). Academy attendees are invited to join lively discussions led by leading eye health experts on topics including cataract surgery, innovative IOL technologies, dry eye and retinal surgery and live demonstrations of the VICTUS® Femtosecond Laser Platform, the Stellaris®, Stellaris® PC Vision Enhancement systems and VersaVit 2.0 vitrectomy systems in the Bausch + Lomb booth (#1824).  In addition, our new expanded retina portfolio, including the Synergetics USA Inc. line of retinal equipment, accessories and instruments, will also be on display in the Bausch + Lomb Synergetics booth (#4737).

Surgical Product & Platform Update
In October, Bausch + Lomb completed its acquisition of Synergetics USA Inc., a world-class supplier of products for retina surgery that includes the VersaVit 2.0 vitrectomy system, Photon Light Source, an extensive array of laser probes and fiber optic illuminators, the DDMS® (Diamond Dusted Membrane Scraper series), the Pinnacle series of single-use instruments, and a broad array of other accessory products for retinal procedures. Attendees are encouraged to view all the new accessories for retina surgery including the Illuminated Directional™ II laser probe and the 27-gauge product line, which will be on display in both the Bausch + Lomb exhibit (#1824) and the Bausch + Lomb Synergetics booth (#4737).

As announced during the summer, 510(k) clearance was received from the FDA for an adjustable chandelier fiber optic illuminator in 23- and 25-gauge versions, which has been designed specifically for the Stellaris® PC Vision Enhancement System. The adjustable chandelier provides uniform, diffused lighting and modifiable light control to help provide excellent intraocular visibility and efficiency during vitreoretinal procedures. The adjustable chandelier fiber and new 23-gauge fragmentation needle will be available for purchase at the Bausch + Lomb booth.

In addition to the Stellaris® PC, attendees can also view the Stellaris® Microsurgical System for cataract surgery. The Stellaris® system has seen significant growth in 2015 (38 percent growth in Q3) with the new optimized Multi-Burst parameters that are used for cataract removal following treatment with the VICTUS® Femtosecond Laser. These technology platforms, combined with Bausch + Lomb’s portfolio of premium advanced optic IOLs, including TRULIGN® Toric IOL, Crystalens® and enVista® IOL, comprise the company’s premium cataract offering and will be on display in the Premium Vision Technology Suite in the exhibit. Live demonstrations of the Stellaris® and Stellaris® PC systems will be available for attendees in the Bausch + Lomb booth. 

Earlier this year, Bausch + Lomb announced the TRULIGN® Toric intraocular lens power range has expanded with the addition of 10.0-16.5 (in half-diopter steps), providing eye care practitioners the full diopter range of the premium lens (from 10.0 to 33.0) for their cataract patients. The TRULIGN® Toric intraocular lens (IOL) calculator was also enhanced to further streamline the TRULIGN® Toric IOL planning process and create a more convenient and accessible tool for surgeons and technicians. Attendees can learn more about the TRULIGN® Toric IOL, which offers a broader range of vision, by visiting the Bausch + Lomb booth during the conference.


Bausch + Lomb’s VICTUS® Femtosecond Laser platform received 510(k) clearance from the FDA for an advanced Swept Source OCT (Optical Coherence Tomography) imaging system and updated software in January. The new software and imaging system allows faster, simpler customized treatment planning compared to the previous system update and delivers auto-recognition of key landmarks on the eye, including the pupil, anterior capsule and posterior capsule, along with the capsule-tilt compensation to maximize lens fragmentation. The platform also recently received 510(k) clearance for an enhanced patient interface kit, which features a smaller diameter clip modified to allow for easier opening and closing, plus a colored suction ring to help facilitate more efficient centration and placement of the clip in patients with narrow fissures and smaller eye openings. Attendees are invited to view the latest updates on the VICTUS® platform at the Bausch + Lomb booth.

New Storz® Ophthalmic Instruments
The Bausch + Lomb Storz® ophthalmic instrument portfolio for refractive, cataract and vitreo-retinal surgery is featuring several new hand-held instruments, which will be on display and available for purchase at the company’s booth (#1824). The new instruments include:

  • The Weir Push/Pull Manipulator – Designed for use during cataract surgery, the instrument’s micro hook allows for multi-axis motions while manipulating iris tissue, IOLs and challenging haptics. The Weir Push/Pull Manipulator fits through a sideport incision.

  • Wortz Femto Wound Hydration Cannula – The Wortz Femto Wound Hydration Cannula delivers precise fluid flow for increased control during wound hydration. The tip design and curve help to facilitate sealing the wound without over-inflating the anterior chamber or over-hydrating the corneal stroma. The instrument is especially useful in femtosecond cataract surgery cases.

  • Palydowycz Eye Speculum – The speculum’s half-wire and half-solid blade offers the advantage of a wire speculum, but extends to contain eyelashes. A spring feature also provides balanced tension to help hold the eye open and to avoid increased ocular pressure.

  • Tran Femto Ergo Chopper – The titanium Tran Femto Ergo Chopper features a capsule-friendly ball tip and angled neck with a horizontal chopping edge. The angulation is designed to help reduce force on the capsule opening when reaching under the anterior chamber and orienting the chopper with the Phaco needle for efficient chopping. The second tip features a blunt spatula, ideal for opening femto corneal incisions.

  • Sadri IOL ManipulatorThis instrument is designed to fi­t through the sideport incision and manipulate the cataract during lens removal. The textured tip is designed to grip the lens during phacoemulsifi­cation while its ball shape helps to reduce the risk of capsule rupture.


Pharmaceuticals Product & Acquisition Update

In October, the company announced it had entered into a definitive agreement to acquire Doctor’s Allergy Formula, LLC, which is being integrated into the company’s pharmaceuticals division. The FDA-approved in-office Doctor’s Allergy Formula test enables eye care practitioners to objectively diagnose and identify the root cause of patient’s ocular allergies utilizing a panel of allergens that are specific to each region of the country. The three minute diagnostic test provides results within 10-15 minutes and the knowledge obtained from the Doctor’s Allergy Formula test results can help physicians identify the offending allergens and aid physicians in developing a customized treatment protocol. Attendees can learn more about the diagnostic test in Bausch + Lomb’s booth.


Many of the company’s pharmaceutical products will also be featured in the Bausch + Lomb booth during the meeting. The proprietary products will include BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%, Lotemax® Gel (loteprednol etabonate ophthalmic gel) 0.5%, Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension), ZIRGAN® (ganciclovir ophthalmic gel) 0.15%, BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL® (timolol maleate ophthalmic solution) 0.5%, Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, Lacrisert® (hydroxypropyl cellulose ophthalmic insert), VISUDYNE® (verteporfin for injection), PROLENSA® (bromfenac ophthalmic solution) 0.07% and the Sjö® diagnostic test.

Featured Retina-Focused Educational Event
Vitreoretinal surgeons are invited to attend “The Retina Sessions: Interactive Discussions on Challenging Cases”, an educational event sponsored by Bausch + Lomb Synergetics, on Friday, Nov. 13 at Surrender Nightclub at Wynn Encore, 3131 Las Vegas Blvd South from 6:30– 8:30 p.m. PT. Session will be moderated by  Asheesh Tewari, M.D. and faculty to include: John Pollock, M.D.; John W. Kitchens, M.D.; Guarav K. Shah, M.D.; Netton Choudhry, M.D.; and Kevin J. Blinder, M.D.   

Leading Experts Host Bausch + Lomb Booth Panel Discussions and Talks

The following leading clinical experts will host a series of presentations and discussions in Bausch + Lomb’s booth:


Saturday, Nov. 14:
1) 10-10:30 a.m. PT - “enVista® IOL: Premium Optics on a Monofocal IOL” by David Goldman, MD; Mitch Jackson, MD; and Kevin Belville, MD

2) 11-11:30 a.m. PT - “Management of the Moderate to Severe Dry Eye Patient” by John Sheppard, MD

3) 1-1:30 p.m. PT - “Sjögren’s Disease and Diagnosis with the Sjö® Diagnostic Test” by Marguerite McDonald, MD

4) 2-2:30 p.m. PT - “Achieving 20/Happy with Premium IOLs” by Farrell 'Toby' Tyson, MD; Afshin James Khodabakhsh, MD; and Eva Liang, MD

Sunday, Nov. 15:

1) 10-10:30 a.m. PT - “
Phaco Technologies for Optimized Femtosecond Cataract Surgery” by Inder Paul Singh, MD; Timothy Page, MD; and Frank Bowden III, MD

2) 11-11:30 a.m. PT - “Technology Advancements and Synergies in Retinal Surgery” by Carl Awh, MD; Asheesh Tewari, MD; and Kevin Blinder, MD  

3) 2-2:30 p.m. PT – “VICTUS®: Versatility Throughout the Anterior Segment” by Michael Collins, MD; Brett Ernst, MD; and Mitch Shultz, MD.      

The full schedule is available at the Bausch + Lomb booth (#1824).

Scientific Podium Presentations and Posters
Several of Bausch + Lomb’s products will be highlighted during podium and poster presentations during the meeting. These will include the following:

  • Ang, Bobby and Hope, Richard. “Three Year Clinical Outcomes Crystalens® vs. Competitor MFIOL: Visual Acuity, Accommodation, Contrast Sensitivity, Starburst & Halos.” [AAO Poster PO283: Hall G (Sands Expo/Venetian), Monday, Nov. 16, 12:30 to 2 p.m. PST].  

  • Sadri, Ehsan; and Ayyagari, Madhu. “New Injector Material and Coating for enVista® and Crystalens®: Prevents IOL Damage and Improve Ease of Insertion.” [AAO Poster PO024: Hall G (Sands Expo/Venetian), Monday, Nov. 16, 12:30 to 2 p.m. PST].  

  • Asbell, P.; Sahm, D.; DeCory, H. “Methicillin-Resistant Staphylococci: Antibiotic Resistance Monitoring in Ocular Micro-organisms, 2014 Results.” [AAO Poster PO311: Hall G (Sands Expo/Venetian), Monday, Nov. 16, 12:30 to 2 p.m. PST]. 

Run for Vision to Support Eye Health
Bausch + Lomb is proud to sponsor the 30th annual Run for Vision, a 5k benefit run/walk, which will begin and finish at the Springs Preserve, a 180-acre cultural institution listed on the National Register of Historic Places, on Sunday, Nov. 15 at 6:30 a.m. PST. Proudly sponsored by Bausch + Lomb for the past 30 years, the annual run is held to help benefit the Eye Bank Association of America (EBAA) and raise awareness and support of eye tissue donation.

Pre-registered runners and walkers can pick up their race packets, including runner bib and t-shirt, at the Bausch + Lomb booth (#1824) inside the Sands Expo and Convention Center (201 Sands Ave, Las Vegas, NV 89169); which is connected to The Venetian and The Palazzo hotels) between 9 a.m. and 5 p.m. on Saturday, Nov. 14. AAO attendees can also sign up for the race in the Bausch + Lomb booth (#1824) or online here.

About TRULIGN® Toric Intraocular Lens 

The TRULIGN® Toric posterior chamber intraocular lens is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia who desire reduction of residual refractive cylinder with increased spectacle independence and improved uncorrected near, intermediate and distance vision.

About Cataract Surgery and Intraocular Lenses  
According to the World Health Organization, there are about 100 million people in the world today who are 80 years old or older.  That number is expected to almost quadruple by 2050.  Aging is the leading cause of eye diseases, such as cataracts.  A cataract is a clouding of the normally clear lens in the eye.  It also happens to be the leading cause of blindness in the world.  According to the National Eye Institute, cataract surgery is one of the safest, most common and effective surgical procedures.  Worldwide, over 20 million cataract surgeries are performed annually. Cataract surgery is a simple procedure during which the natural lens in the patient's eye is surgically replaced with an IOL.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. 

Visudyne is a trademark of Novartis A.G. under license.
All other ®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
© Bausch & Lomb Incorporated

News Media Contacts:

Kristy Marks
PR Product Manager, Bausch + Lomb

(585) 338-8095 or


Teresa Panas
BioComm Network, on behalf of Bausch + Lomb
(973) 809-8590 or

Tad Heitmann
BioComm Network, on behalf of Bausch + Lomb
(714) 273-2937 or


Actions: E-mail | Permalink |